WO2024059525A3 - Composés et procédés pour la dégradation ciblée de la kinase du lymphome anaplasique et de la ros1 kinase - Google Patents
Composés et procédés pour la dégradation ciblée de la kinase du lymphome anaplasique et de la ros1 kinase Download PDFInfo
- Publication number
- WO2024059525A3 WO2024059525A3 PCT/US2023/073910 US2023073910W WO2024059525A3 WO 2024059525 A3 WO2024059525 A3 WO 2024059525A3 US 2023073910 W US2023073910 W US 2023073910W WO 2024059525 A3 WO2024059525 A3 WO 2024059525A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ros1
- compounds
- kinase
- alk
- methods
- Prior art date
Links
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 title abstract 6
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 title abstract 6
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 230000015556 catabolic process Effects 0.000 title abstract 2
- 238000006731 degradation reaction Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 101100091501 Mus musculus Ros1 gene Proteins 0.000 title 1
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 abstract 4
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 abstract 4
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 abstract 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 abstract 1
- 230000001588 bifunctional effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 230000017854 proteolysis Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
L'invention concerne des composés de formule (I) : ou un sel, un hydrate, un solvate, un promédicament, un stéréoisomère ou un tautomère pharmaceutiquement acceptable de ceux-ci, qui agissent en tant que fractions induisant une dégradation de protéine pour une kinase de lymphome anaplasique (ALK) et ROS1. Ces composés sont utiles dans des procédés pour la dégradation ciblée de ALK et ROS1 par l'utilisation des composés bifonctionnels qui lient une fraction de liaison à l'ubiquitine ligase à un ligand qui est capable de se lier à ALK et ROS1 qui peut être utilisé dans le traitement de troubles modulés par ALK et ROS1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263375292P | 2022-09-12 | 2022-09-12 | |
| US63/375,292 | 2022-09-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2024059525A2 WO2024059525A2 (fr) | 2024-03-21 |
| WO2024059525A3 true WO2024059525A3 (fr) | 2024-04-18 |
Family
ID=90275799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2023/073910 WO2024059525A2 (fr) | 2022-09-12 | 2023-09-12 | Composés et procédés pour la dégradation ciblée de la kinase du lymphome anaplasique et de la ros1 kinase |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2024059525A2 (fr) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020069106A1 (fr) * | 2018-09-27 | 2020-04-02 | Dana-Farber Cancer Institute, Inc. | Agents de dégradation ciblant l'alk et leurs utilisations thérapeutiques |
| US20200306273A1 (en) * | 2017-12-13 | 2020-10-01 | Shanghaitech University | Alk protein degradation agent and anti-tumor application thereof |
| WO2021083555A1 (fr) * | 2019-10-28 | 2021-05-06 | Universitetet I Oslo | Inhibiteurs d'alk pour le traitement du cancer alk-négatif et de maladies médiées par des cellules plasmatiques |
| US20210283261A1 (en) * | 2017-12-05 | 2021-09-16 | Icahn School Of Medicine At Mount Sinai | Compositions and Methods for Treating ALK-Mediated Cancer |
| US20220064196A1 (en) * | 2019-01-17 | 2022-03-03 | Betta Pharmaceuticals Co., Ltd. | EGFR Inhibitors, Compositions and Methods Thereof |
-
2023
- 2023-09-12 WO PCT/US2023/073910 patent/WO2024059525A2/fr unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210283261A1 (en) * | 2017-12-05 | 2021-09-16 | Icahn School Of Medicine At Mount Sinai | Compositions and Methods for Treating ALK-Mediated Cancer |
| US20200306273A1 (en) * | 2017-12-13 | 2020-10-01 | Shanghaitech University | Alk protein degradation agent and anti-tumor application thereof |
| WO2020069106A1 (fr) * | 2018-09-27 | 2020-04-02 | Dana-Farber Cancer Institute, Inc. | Agents de dégradation ciblant l'alk et leurs utilisations thérapeutiques |
| US20220064196A1 (en) * | 2019-01-17 | 2022-03-03 | Betta Pharmaceuticals Co., Ltd. | EGFR Inhibitors, Compositions and Methods Thereof |
| WO2021083555A1 (fr) * | 2019-10-28 | 2021-05-06 | Universitetet I Oslo | Inhibiteurs d'alk pour le traitement du cancer alk-négatif et de maladies médiées par des cellules plasmatiques |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024059525A2 (fr) | 2024-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEP20227433B (en) | 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors | |
| WO2021086833A8 (fr) | Inhibiteurs à petites molécules de mutant de kras g12c | |
| IL260127B (en) | mek inhibitors and methods of using them | |
| TW200640883A (en) | Compounds for the treatment of proliferative disorders | |
| WO2021055728A8 (fr) | Inhibiteurs à petites molécules de mutant de kras g12c | |
| TW200716570A (en) | Compounds for the treatment of proliferative disorders | |
| GEP20084439B (en) | Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof | |
| NO20084496L (no) | Pyridyl- og pyrimidinylsubstituerte pyrrol-, tiofen- og furanderivater som kinaseinhibitorer | |
| MX2008002061A (es) | Derivados de tiazolil piperidina utiles como moduladores del receptor h3. | |
| WO2006067614A3 (fr) | Derives heteroaromatiques utiles en tant qu'agents anticancereux | |
| PT1608647E (pt) | Derivados de 5-feniltiazole e sua utilização como inibidores da quinase p13 | |
| MY156407A (en) | 5-phenylthiazole derivatives and use as p13 kinase inhibitors | |
| WO2004087698A3 (fr) | Thiazoles utiles en tant qu'inhibiteurs de proteines kinases | |
| MXPA05012466A (es) | Derivados de quinolina como inhibidores de fosfodiesterasa. | |
| MX2010003927A (es) | Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas cinasas b. | |
| WO2005005378A3 (fr) | Hydrazides d'indolinone utilises en tant qu'inhibiteurs du recepteur c-met | |
| WO2007035620A3 (fr) | Derives de carbazole | |
| TW200612936A (en) | Indole derivatives | |
| WO2008151288A3 (fr) | Composés aromatiques et hétéroaromatiques utiles dans le traitement de troubles du métabolisme du fer | |
| WO2005004808A3 (fr) | Composes tetracycliques utilises comme inhibiteurs de c-met | |
| GB0112348D0 (en) | Compounds | |
| WO2008130879A3 (fr) | Dérivés de tétrahydroindole et de tétrahydroindazole | |
| MX2021011118A (es) | Derivados de azolopiridina macrocíclicos como moduladores de eed y prc2. | |
| WO2006077024A3 (fr) | Derives de 5-aminoindole | |
| IL191751A0 (en) | Pyrrolo[2,3-c]pyridine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23866370 Country of ref document: EP Kind code of ref document: A2 |